In hypertensive patients with comorbidities, the lowest risk of cardiovascular events occurred at a post-treatment systolic blood pressure of 110-119 mm Hg, while all-cause mortality was lowest at 120-129 mm Hg.
Cohort (n=22,546)
No
Does the optimal post-treatment systolic blood pressure target differ for reducing CVD events and mortality in hypertensive patients with versus without comorbidities?
The ideal post-treatment SBP in hypertensive patients with comorbidities should be individualized, targeting 120-130 mm Hg for those with shorter life expectancy and 110-120 mm Hg for those with longer life expectancy.
The effect of hypertension on cardiovascular disease is increasingly evident, but the effect of hypertension with chronic medical conditions on adverse outcomes is less clear. To explore the minimum threshold range of target systolic blood pressure (SBP) in hypertensive population with comorbidities. A total of 11,388 hypertensive participants with comorbidities in the Kailuan cohort were selected. Propensity score matching (PSM) was also conducted among the 27,541 participants who suffered from hypertension without comorbidities and had received a physical examination in the same period. Finally, totaling 22,546 participants. After a follow-up of more than 7 years, the occurrence rate of CVD events in hypertensive participants with comorbidities was the minimum in the 110 ≤ SBP < 120 mm Hg group; the occurrence rate of CVD events in hypertensive participants without comorbidities was the minimum in the SBP < 110 mm Hg group; the all-cause mortality in participants with comorbidities and without comorbidities were the minimum in the 120 ≤ SBP < 130 mm Hg group. The results of the time-dependent Cox model and death competition risk model used in the two groups were consistent with those of the master model. The ideal post-treatment SBP in participants with comorbidities should be individualized. If the patient has a short life expectancy, his/her post-treatment SBP should be kept at 120 to 130 mm Hg. If the patient has a long life expectancy, his/her post-treatment SBP should be kept at 110 to 120 mm Hg.
Huang et al. (Mon,) conducted a cohort in Hypertension with and without comorbidities (n=22,546). Post-treatment systolic blood pressure (SBP) vs. 110-119 mm Hg (for CVD) and 120-129 mm Hg (for mortality) was evaluated on De novo cardiovascular disease (CVD) events and all-cause mortality. In hypertensive patients with comorbidities, the lowest risk of cardiovascular events occurred at a post-treatment systolic blood pressure of 110-119 mm Hg, while all-cause mortality was lowest at 120-129 mm Hg.